Fred Hutch’s Climb to Fight Cancer is the perfect platform for outdoor enthusiasts to connect their love of climbing to raising awareness and funds for cancer research. In July I’ll be climbing Mt. Kilimanjaro as part of Luke Timmerman’s Kilimanjaro Climb to Fight Cancer team and have committed to raising $50,000 for cancer research. 

In support of this effort, I’ve gathered a group of thought leaders, biotech execs, investors, and entrepreneurs in the Boston community to share their perspectives at the Emerging Frontiers in Oncology Summit. Together, we will discuss and debate the drivers of future breakthroughs in oncology across three major domains: 

• Research: Driving breakthroughs at the source — the bench. Where is funding allocated, and how will it shape the future pipeline? 
• Innovation: What’s ready for primetime? Are we still riding a wave, or is another one on the way?  
• People: If we build it, will they come – Finding and fostering talent to lead oncology newcos. 

We’ve seen many important advances in oncology in recent years, from next-generation targeted therapies to immunotherapies and engineered cell therapies. The summit aims to facilitate a provocative discussion on what will drive the innovations yet to come.

Proceeds benefit the Climb to Fight Cancer at Fred Hutchinson Cancer Research Center.

Cocktails and networking will take place at Catalyst Restaurant (300 Technology Square, Cambridge, MA 02139) from 6:30-8:30 p.m.

Together, I know we can make a difference in the fight against cancer. Thank you for your support!

Uciane Scarlett
Atlas Venture

AGENDA

2:30 p.m. | Registration

3:00 p.m. | Welcome Remarks

• Uciane Scarlett, associate, Atlas Venture

3:05 p.m. | Research: Driving breakthroughs at the source — the bench (2-way fire side chat)

• Howard Kaufman, CMO, Replimune; Professor, MGH 
• Alan D’Andrea, Professor, DFCI  

3:50 p.m. | Innovation Bridge: Title TBD (presentation)

• Clarion

4:20 p.m. | Innovation: What’s ready for primetime? Are we still riding a wave, or is another one on the way? (debate-style panel)

• Ben Auspitz, partner, F-Prime
• Christoph Lengauer, partner, Third Rock Ventures
• David Kaufman, CMO, Bill & Melinda Gates MRI
• David Ting, assistant professor, MGH
• Erikk Anderson, CEO and founder of Alloy Therapeutics
• Keith Flaherty, professor, MGH; director, Termeer Center
• Nancy Simonian, CEO, Syros
• Clarion (moderator)

5:20 p.m. | People: If we build it, will they come? (round table)

• Jean-Francois Formela, partner, Atlas Venture
• Jeffrey Walsh, Chief Strategy Officer, Bluebird Bio
• Joanna Horobin, CMO, Idera Pharma
• Peter Smith, entrepreneur in residence, Atlas Venture
• Shin Fuse, managing director, MPM
• Luke Timmerman, Timmerman Report (moderator)

6:20 p.m. | Closing Remarks, A Word on the Kilimanjaro Climb to Fight Cancer

• Uciane Scarlett
• Luke Timmerman

6:30 p.m. | NETWORKING

8:00 p.m. | END 

Sponsored by: 

• Alexandria
• Clarion
• LEK 

Hosted by: 

• Mass Bio